Health
Roche Struggles to Regain Momentum After a Difficult Year
- Drugmaker’s outlook for 2024 is below analysts’ estimates
- Shares drop the most in three months in early trading
This article is for subscribers only.
Roche Holding AG forecast a sluggish recovery in sales and earnings this year as it emerges from a difficult 2023 and a string of research setbacks.
Sales and earnings per share excluding some items will grow in the mid-single-digit range at constant currencies, the Swiss drugmaker said Thursday. That’s below analyst expectations, though better than Roche’s prediction a year ago.